Clinical studies demonstrate elevated serum IL-1β levels in CKD patients correlate with coronary calcification scores, while NLRP3 inhibition with MCC950 suppresses IL-1β secretion and attenuates calcification (35). Here, NLRP3 is linked to chronic kidney disease.